495 / 1084
Trastuzumab in Oesophageal Adenocarcinoma (Toga)
Anti-EGFR antibodies (Cetuximab, Panitumumab)
Bang et al.
Lancet
2010
Oesophageal Cancer
„Personalized Medicine“
Only one positive approach thus far: Trastuzumab in HER2+++ adenocarcinoma
EGFR-directed tyrosine kinase inhibitors (Gefitinib)
MET / HGF directed antibodies (Onartuzumab, Rilotumumab)
Lordick et al.
Lancet Oncol
2013
Waddell et al.
Lancet Oncol
2013
Dutton et al.
Lancet Oncol
2014
Shah et al.
JAMA Oncol
2016
Cunningham et al
. ASCO 2015